Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7527938 | 0.88 | PDGFRB (0.49) | PDGFRBEGFRMAPK1KMT2APDE5A | |
| SCHEMBL7521455 | 0.88 | EGFR (0.48) | PDGFRBEGFRMAPTMAPK1KMT2A | |
| SCHEMBL7526254 | 0.88 | EGFR (0.48) | PDGFRBEGFRMAPTMAPK1KMT2A | |
| SCHEMBL7527697 | 0.88 | EGFR (0.48) | PDGFRBEGFRMAPTMAPK1KMT2A | |
| SCHEMBL7530560 | 0.88 | EGFR (0.48) | PDGFRBEGFRMAPTMAPK1KMT2A | |
| SCHEMBL7527163 | 0.86 | PDGFRB (0.48) | PDGFRBEGFRMAPTMAPK1KMT2A | |
| SCHEMBL7528018 | 0.86 | EGFR (0.47) | PDGFRBEGFRMAPTMAPK1KMT2A | |
| SCHEMBL7514367 | 0.86 | MAPT (0.48) | PDGFRBEGFRMAPTLMNAKMT2A | |
| SCHEMBL7521565 | 0.85 | PDGFRB (0.47) | PDGFRBEGFRMAPTMAPK1PDE5A | |
| SCHEMBL7521285 | 0.83 | PDE5A (0.58) | PDGFRBEGFRMAPTMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193389-A1 | Method of inhibiting neoplastic cells with imidazoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-12-19 | — | — | US | disclosed |
| US-6127541-A | 8-((DISUBSTITUTED AMINO)BENZYLAMINO)-2,3-DIHYDRO-1H-IMIDAZO(4,5-G)QUINAZOLINE-(2-THIONE OR 2-ONE); SELECTIVE CYCLIC GUANOSINE 3',5' MONOPHOSPHATE (CGMP)--SPECIFIC PHOSPHODIESTERASE (PDE) INHIBITORY ACTIVITY | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| EP-0863144-A1 | IMIDAZOQUINAZOLINE DERIVATIVES | Kyowa Hakko Co., Ltd. (JP) | 1998-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193389-A1 | Method of inhibiting neoplastic cells with imidazoquinazoline derivatives | MKI67, HRAS, VHL | PDGFRB 3113/4885EGFR 3583/4885MAPT 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.